MPP Unveils Quartet Of Nilotinib Licensees
Four Firms Agree To Produce Generic Versions Of Tasigna Under Licensing Deal
Details of the four firms that have been selected to manufacture generic versions of Novartis’s nilotinib treatment for chronic myeloid leukemia have been revealed by the Medicines Patent Pool.
